The pulsed field ablation (PFA) modality for cardiac arrhythmia treatment continues its rapid ascent with major funding rounds and clinical advancement. Field Medical Inc. secured an additional $35 million in series B financing following strong pilot data showcasing efficacy in ventricular tachycardia ablation. Similarly, Kardium Inc. raised C$340 million (US$250 million) to support commercialization of its Globe PFA system for atrial fibrillation, with anticipated FDA approval this quarter. Clinical data confirms high procedural success rates and favorable safety profiles, underscoring PFA’s potential to revolutionize electrophysiology.